Senti Bio to Present at MedInvest Conference on Sept 24
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, will participate in the upcoming MedInvest Biotech & Pharma Conference in Palo Alto, California.
Dr. Kanya Rajangam, President, Head of Research & Development and Chief Medical Officer, will deliver a presentation on Wednesday, September 24, 2025, at 9:55 AM PT. The management team will also be available for one-on-one meetings with qualified investors attending the conference.
A live webcast of the presentation will be accessible through the Events page in the Investors section of sentibio.com.
Senti Biosciences (Nasdaq: SNTI), una biotecnologia a stadio clinico focalizzata sullo sviluppo di terapie cellulari e geniche di nuova generazione, parteciperà alla prossima conferenza MedInvest Biotech & Pharma a Palo Alto, California.
Dr. Kanya Rajangam, Presidente, Capo Ricerca e Sviluppo e Direttore Medico, terrà una presentazione mercoledì 24 settembre 2025 alle 9:55 ora del Pacifico. Il team esecutivo sarà disponibile anche per incontri individuali con investitori qualificati presenti alla conferenza.
Una trasmissione in diretta della presentazione sarà accessibile tramite la pagina Eventi nella sezione Investitori di sentibio.com.
Senti Biosciences (Nasdaq: SNTI), una empresa de biotecnología en etapa clínica centrada en desarrollar terapias celulares y génicas de próxima generación, participará en la próxima MedInvest Biotech & Pharma Conference en Palo Alto, California.
La Dra. Kanya Rajangam, Presidenta, Jefa de Investigación y Desarrollo y Directora Médica, ofrecerá una presentación el miércoles 24 de septiembre de 2025 a las 9:55 a.m. hora del Pacífico. El equipo directivo también estará disponible para reuniones individuales con inversores calificados que asistan a la conferencia.
Una transmisión en vivo de la presentación estará disponible a través de la página de Eventos en la sección de Inversores de sentibio.com.
Senti Biosciences (Nasdaq: SNTI), 차세대 세포 및 유전자 치료제를 개발하는 임상단계 생명공학 기업은 팔로 알토, 캘리포니아에서 열리는 MedInvest Biotech & Pharma Conference에 참석합니다.
Dr. Kanya Rajangam, 사장 겸 연구개발총괄 및 최고의료책임자는 2025년 9월 24일 수요일, 오후 9:55 PDT에 발표를 진행합니다. 경영진은 또한 컨퍼런스에 참석하는 자격 있는 투자자들과의 일대일 미팅도 가능할 예정입니다.
발표의 라이브 웹캐스트는 sentibio.com의 투자자 섹션 이벤트 페이지를 통해 시청할 수 있습니다.
Senti Biosciences (Nasdaq: SNTI), une société de biotechnologie en phase clinique axée sur le développement de thérapies cellulaires et géniques de prochaine génération, participera à la prochaine MedInvest Biotech & Pharma Conference à Palo Alto, Californie.
Dr. Kanya Rajangam, présidente, responsable de la Recherche et Développement et directrice médicale, fera une présentation le mercredi 24 septembre 2025 à 9h55 PT. L’équipe de direction sera également disponible pour des entretiens individuels avec les investisseurs qualifiés présents à la conférence.
Une diffusion en direct de la présentation sera accessible via la page Événements dans la section Investisseurs de sentibio.com.
Senti Biosciences (Nasdaq: SNTI), ein biotechnologisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von Therapien der nächsten Generation im Bereich Zell- und Gentherapien konzentriert, wird an der kommenden MedInvest Biotech & Pharma Conference in Palo Alto, Kalifornien, teilnehmen.
Dr. Kanya Rajangam, Präsidentin, Leiterin Forschung & Entwicklung und Chief Medical Officer, wird am Mittwoch, dem 24. September 2025, um 9:55 Uhr PT eine Präsentation halten. Das Management-Team steht auch für Einzelgespräche mit qualifizierten Investoren während der Konferenz zur Verfügung.
Eine Live-Übertragung der Präsentation ist über die Veranstaltungsseite im Investorenbereich von sentibio.com zugänglich.
Senti Biosciences (Nasdaq: SNTI)، شركة تكنولوجيا حيوية في مرحلتها السريرية تركز على تطوير علاجات جينية وخلوية من الجيل التالي، ستشارك في مؤتمر MedInvest Biotech & Pharma القادم في بالو ألتو، كاليفورنيا.
الدكتورة كانيا راجانجام، الرئيسة والمديرة البحثية والتطويرية ورئيسة الطب، ستقدم عرضاً في الأربعاء 24 سبتمبر 2025 الساعة 9:55 صباحاً بتوقيت المحيط الهادئ. كما سيكون فريق الإدارة متاحاً لعقد اجتماعات فردية مع مستثمرين مؤهلين يحضرون المؤتمر.
سيكون البث المباشر للعرض متاحاً من خلال صفحة الأحداث في قسم المستثمرين من sentibio.com.
Senti Biosciences (Nasdaq: SNTI)，一家处于临床阶段、专注于开发下一代细胞与基因治疗的生物技术公司，将参加在加州帕洛阿尔托举行的MedInvest Biotech & Pharma Conference。
Kanya Rajangam 博士，总统、研发负责人及首席医疗官，将在2025年9月24日星期三，太平洋夏令时上午9:55进行演讲。管理团队也将出席会议，与合格投资者进行一对一会面。
演讲的实时网络直播可通过 sentibio.com 的投资者板块的活动页面获取。
Live webcast presentation on Wednesday, September 24th at 9:55 AM PT
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, will present on Wednesday, September 24, 2025 at 9:55 AM PT at the MedInvest Biotech & Pharma Conference being held in Palo Alto, California.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (sentibio.com)
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
When is Senti Biosciences (SNTI) presenting at the MedInvest Conference?
Senti Biosciences will present on Wednesday, September 24, 2025, at 9:55 AM PT at the MedInvest Biotech & Pharma Conference in Palo Alto, California.
Who will be presenting for Senti Biosciences at the MedInvest Conference?
Dr. Kanya Rajangam, who serves as President, Head of Research & Development and Chief Medical Officer of Senti Biosciences, will deliver the presentation.
How can investors access Senti Biosciences’ MedInvest Conference presentation?
Investors can access the live webcast of the presentation through the Events page in the Investors section of Senti Biosciences’ website (sentibio.com).
What type of company is Senti Biosciences (SNTI)?
Senti Biosciences is a clinical-stage biotechnology company that develops next-generation cell and gene therapies using its proprietary Gene Circuit platform.
Credit: Source link
